DGX241220C70000
- 0.00
- 0.000.00%
Quest Diagnostics Newsroom
BofA Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $182
Quest Diagnostics Price Target Announced at $185.00/Share by Jefferies
Quest Diagnostics Analyst Ratings
Jefferies Initiates Quest Diagnostics(DGX.US) With Buy Rating, Announces Target Price $185
Baird Maintains Quest Diagnostics(DGX.US) With Buy Rating, Cuts Target Price to $181
Baird Adjusts Price Target on Quest Diagnostics to $181 From $182, Keeps Outperform Rating
Quest Diagnostics: Balancing Consistent Performance With Growth Constraints – Hold Rating Maintained
Mizuho Securities Maintains Quest Diagnostics(DGX.US) With Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Equillium (EQ), Quest Diagnostics (DGX) and Alnylam Pharma (ALNY)
Quest Diagnostics Analyst Ratings
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $165
Piper Sandler Reaffirms Their Hold Rating on Quest Diagnostics (DGX)
Jefferies Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $175
Quest Diagnostics (DGX) Receives a Buy From Jefferies
Argus Research Maintains Quest Diagnostics(DGX.US) With Buy Rating, Raises Target Price to $175
Quest Diagnostics: Balanced Risk and Reward Justifies Hold Rating Amid Growth and Margin Challenges
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $165 to $185
Quest Upgraded to Outperform by Baird, Sector Momentum Cited
Quest Diagnostics Is Maintained at Buy by Citigroup
A Quick Look at Today's Ratings for Quest Diagnostics(DGX.US), With a Forecast Between $165 to $185